Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A carcinoma that arises from the transitional epithelium of the renal pelvis. It is associated with tobacco use and usually presents with gross or microscopic hematuria. Urothelial carcinomas of the renal pelvis are usually of higher grade and higher stage compared to bladder urothelial carcinomas.
Biomarker and diagnostic research for renal pelvis urothelial carcinoma has been reported in the published literature.
11 clinical trials registered, 2 recruiting. Interventions under study include drug therapy, procedural interventions, biologic therapy, and other interventions. Pipeline includes 2 PHASE3, 5 PHASE2, 2 PHASE1. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT05874921](https://clinicaltrials.gov/study/NCT05874921) |
Data assembled from 3 of 12 sources · Last updated Sep 20, 2026, 8:44 AM UTC
uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto |
— |
UroGen Pharma Ltd. |
RECRUITING |
[NCT05987241](https://clinicaltrials.gov/study/NCT05987241) | Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study | PHASE2 | National Cancer Institute (NCI) | RECRUITING |
65 publications have been identified in PubMed for renal pelvis urothelial carcinoma. Research spans Case Report / Case Series (35%), Review / Meta-Analysis (20%), and Epidemiology / Natural History (20%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 23 | 35% |
Research summaries | 13 | 20% |
Disease patterns and progression | 13 | 20% |
Clinical study results | 8 | 12% |
Testing and diagnosis research | 6 | 9% |
Laboratory research | 2 | 3% |
Guan B (2026). [PMID: 41677900](https://pubmed.ncbi.nlm.nih.gov/41677900/). *World J Urol*. [Diagnostic / Biomarker]
Kohut-Jackson A (2026). [PMID: 41238419](https://pubmed.ncbi.nlm.nih.gov/41238419/). *Clin Genitourin Cancer*. [Clinical Trial Publication]
Xie R (2026). [PMID: 41680068](https://pubmed.ncbi.nlm.nih.gov/41680068/). *Clin Genitourin Cancer*. [Epidemiology / Natural History]
Xu Y (2026). [PMID: 41724966](https://pubmed.ncbi.nlm.nih.gov/41724966/). *BMC Urol*. [Case Report / Case Series]
Di Bello F (2026). [PMID: 39789348](https://pubmed.ncbi.nlm.nih.gov/39789348/). *J Racial Ethn Health Disparities*. [Epidemiology / Natural History]
Wang S (2026). [PMID: 41894298](https://pubmed.ncbi.nlm.nih.gov/41894298/). *Medicine (Baltimore)*. [Clinical Trial Publication]
Deng Z (2026). [PMID: 42172026](https://pubmed.ncbi.nlm.nih.gov/42172026/). *JAMA Netw Open*. [Review / Meta-Analysis]
Bahlinger V (2026). [PMID: 41587739](https://pubmed.ncbi.nlm.nih.gov/41587739/). *Aktuelle Urol*. [Review / Meta-Analysis]
Farzat M (2026). [PMID: 41615910](https://pubmed.ncbi.nlm.nih.gov/41615910/). *PLoS One*. [Clinical Trial Publication]
Korn P (2026). [PMID: 42171772](https://pubmed.ncbi.nlm.nih.gov/42171772/). *World J Urol*. [Clinical Trial Publication]